{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T10:24:50Z","timestamp":1775989490718,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["FNOs 2015"],"award-info":[{"award-number":["FNOs 2015"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12872-017-0602-6","type":"journal-article","created":{"date-parts":[[2017,6,26]],"date-time":"2017-06-26T12:58:15Z","timestamp":1498481895000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1484-6413","authenticated-orcid":false,"given":"Leos","family":"Pleva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Kukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Zapletalova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ota","family":"Hlinomaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,26]]},"reference":[{"key":"602_CR1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1755-5922.2010.00155.x","volume":"29","author":"MS Kim","year":"2011","unstructured":"Kim MS, Dean LS. In-Stent Restenosis. Cardiovascular Therapeutic. 2011;29:190\u20138.","journal-title":"Cardiovascular Therapeutic"},{"key":"602_CR2","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1016\/j.jacc.2014.02.545","volume":"63","author":"F Alfonso","year":"2014","unstructured":"Alfonso F, Byrne RA, Rivero F, Kastrati A. Current treatment of in-stent restenosis. JACC. 2014;63:2659\u201373.","journal-title":"JACC"},{"issue":"3","key":"602_CR3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/01.rli.0000116125.96544.64","volume":"39","author":"U Speck","year":"2004","unstructured":"Speck U, Scheller B, Abramjuk C, Grossmann S, Mahnkopf D, Simon O. Inhibition of restenosis in stented porcine coronary arteries: uptake of paclitaxel from angiographic contrast media. Investig Radiol. 2004;39(3):182\u20136.","journal-title":"Investig Radiol"},{"key":"602_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.115.003316","volume":"9","author":"L Pleva","year":"2016","unstructured":"Pleva L, Kukla P, Kusnierova P, Zapletalova J, Hlinomaz O. Comparison of the efficacy of paclitaxel-eluting balloon catheters and Everolimus-eluting stents in the treatment of coronary in-stent restenosis. The Treatment of In-Stent Restenosis Study Circ Cardiovasc Interv. 2016;9:e003316. doi: 10.1161\/CIRCINTERVENTIONS.115.003316 .","journal-title":"The Treatment of In-Stent Restenosis Study Circ Cardiovasc Interv"},{"key":"602_CR5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jacc.2007.07.084","volume":"51","author":"SJ Pocock","year":"2008","unstructured":"Pocock SJ, Lansky AJ, Mehran R, Popma JJ, Fahy MP, Na Y, et al. Angiogaphic surrogate end points in drug-eluting stent trials. JACC. 2008;51:23\u201332.","journal-title":"JACC"},{"key":"602_CR6","doi-asserted-by":"crossref","first-page":"80","DOI":"10.33590\/emjintcardiol\/10312835","volume":"1","author":"B Vaquerizo","year":"2013","unstructured":"Vaquerizo B, Aizpurua DA, Cuscullida JC, Pe\u00f1aranda AS. Update on drug-eluting balloons for percutaneous coronary interventions. EMJ Int Cardiol. 2013;1:80\u201390.","journal-title":"EMJ Int Cardiol"},{"key":"602_CR7","unstructured":"van Driel A, Ijsselmuiden S, Polad J, Scholte M, Vries A, Weevers A. Interim results of a new paclitaxel-coated DEB in real-world PCI indications. [Abstract].In: Abstracts of EuroPCR 2016, Paris, France, Euro 16A\u2013POS0885. http:\/\/www.pcronline.com\/eurointervention\/AbstractsEuroPCR2016_issue\/abstracts-europcr-2016\/ . Accessed on October 28, 2016."},{"key":"602_CR8","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1093\/eurheartj\/ehs184","volume":"33","author":"K Thygesen","year":"2012","unstructured":"Thygesen K, Albert JS, Jafe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. EHJ. 2012;33:2551\u201367.","journal-title":"EHJ"},{"key":"602_CR9","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials. A case for standardized definitions. Circulation. 2007;115:2344\u201351.","journal-title":"Circulation"},{"key":"602_CR10","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1161\/01.CIR.78.2.486","volume":"78","author":"TJ Ryan","year":"1988","unstructured":"Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB, Loop FD, et al. Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology\/American Heart Association task force on the Assesment of diagnostic and therapeutic cardiovascular procedures. Circulation. 1988;78:486\u2013502.","journal-title":"Circulation"},{"key":"602_CR11","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1161\/01.CIR.100.18.1872","volume":"100","author":"R Mehran","year":"1999","unstructured":"Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, et al. Angiographic patterns of in-stent restenosis classification and implications for long-term outcome. Circulation. 1999;100:1872\u20138.","journal-title":"Circulation"},{"key":"602_CR12","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/01.CIR.0000138929.71660.E0","volume":"110","author":"B Scheller","year":"2004","unstructured":"Scheller B, Speck U, Abramjuk C, Bernhardt U, B\u00f6hm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004;110:810\u20134.","journal-title":"Circulation"},{"key":"602_CR13","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa061254","volume":"355","author":"B Scheller","year":"2006","unstructured":"Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated ballon catheter. NEJM. 2006;355:2113\u201324.","journal-title":"NEJM"},{"key":"602_CR14","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1161\/CIRCULATIONAHA.108.839282","volume":"119","author":"M Unverdorben","year":"2009","unstructured":"Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009;119:2986\u201394.","journal-title":"Circulation"},{"key":"602_CR15","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jacc.2013.12.006","volume":"63","author":"F Alfonso","year":"2014","unstructured":"Alfonso F, P\u00e9rez-Vizcayno MJ, C\u00e1rdenas A, del Blanco BG, Seidelberger B, I\u0144iguez A, et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent in-stent restenosis. JACC. 2014;63:1378\u201386.","journal-title":"JACC"},{"key":"602_CR16","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4244\/EIJV8I4A70","volume":"8","author":"P Bondesson","year":"2012","unstructured":"Bondesson P, Lagerqvist B, James SK, Olivecrona GK, Venetsanos D, Harnek J. Comparison of two drug-eluting balloons: a report from the SCAAR registry. EuroInterv. 2012;8:444\u20139.","journal-title":"EuroInterv"},{"key":"602_CR17","doi-asserted-by":"publisher","unstructured":"Nijhoff F, Stella PR, Troost MS, Belkacemi A, Nathoe HM, Voskuil M, et al. Comparative assessment of the antirestenotic efficacy of two paclitaxel drug-eluting balloons with different coatings in the treatment of in-stent restenosis. Clin Res Cardiol 2015;11p.doi: 10.1007\/s00392-015-0934-0.","DOI":"10.1007\/s00392-015-0934-0."},{"issue":"6","key":"602_CR18","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jacc.2013.09.043","volume":"63","author":"G Campo","year":"2014","unstructured":"Campo G, Tebaldi M, Vranckx P, Biscaglia S, Tumscitz C, Ferrari R, et al. Short- Versus Long-Term Duration of Dual Antiplatelet Therapy in Patients Treated for In-Stent Restenosis A PRODIGY Trial Substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). JACC. 2014;63(6):506\u201312.","journal-title":"JACC"},{"key":"602_CR19","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","volume":"125","author":"M Valgimigli","year":"2012","unstructured":"Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al. Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting A Randomized Multicenter Trial. Circulation. 2012;125:2015\u201326.","journal-title":"Circulation"},{"issue":"2","key":"602_CR20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijcard.2014.03.028","volume":"173","author":"G Campo","year":"2014","unstructured":"Campo G, Punzetti S, Malagu M, Ferrari R, Valgimigli M. Two-year outcomes after first- or second-generation drug-eluting stent implantation in patients with in-stent restenosis. A PRODIGY trial substudy. Int Journal of Cardiol. 2014;173(2):343\u20135.","journal-title":"Int Journal of Cardiol"},{"key":"602_CR21","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ahj.2010.07.034","volume":"160","author":"M Valgimigli","year":"2010","unstructured":"Valgimigli M, Campo G, Percoco G, Monti M, Ferrari F, Tumscitz C, et al. Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention: design and rationale for the PROlonging dual-antiplatelet treatment after Grading stent-induced intimal hyperplasia study (PRODIGY). Am Heart J. 2010;160:804\u201311.","journal-title":"Am Heart J"},{"issue":"1","key":"602_CR22","first-page":"20","volume":"7","author":"M Valgimigli","year":"2014","unstructured":"Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, et al. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention a pre-specified analysis from the PRODIGY study (PROlonging dual antiplatelet treatment after Grading stent-induced intimal hyperplasia studY). JACC: Cardiovasc Interv. 2014;7(1):20\u20138.","journal-title":"JACC: Cardiovasc Interv"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-017-0602-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T04:54:42Z","timestamp":1692852882000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-017-0602-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,26]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["602"],"URL":"https:\/\/doi.org\/10.1186\/s12872-017-0602-6","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,26]]},"article-number":"168"}}